KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Net Income towards Common Stockholders fell 289.96% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 16011.92%. This contributed to the annual value of -$4.8 million for FY2024, which is 9773.98% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Net Income towards Common Stockholders is -$32.0 million, which was down 289.96% from -$13.4 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Net Income towards Common Stockholders high stood at $58.2 million for Q1 2024, and its period low was -$90.9 million during Q1 2021.
  • Over the past 5 years, Esperion Therapeutics' median Net Income towards Common Stockholders value was -$51.6 million (recorded in 2023), while the average stood at -$42.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Net Income towards Common Stockholders surged by 19246.41% in 2024, and later tumbled by 17129.71% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Net Income towards Common Stockholders stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then plummeted by 53.58% to -$32.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$32.0 million for Q3 2025, versus -$13.4 million for Q2 2025 and -$41.5 million for Q1 2025.